CARDINAL HEALTH INC (CAH) Form 8-K — Aug 11, 2026

$CAHForm 8-KItems 2.02, 7.01, 9.01Filed Aug 11, 2026, 6:47 AM ET0000721371-26-000037Original filing

Cardinal Health reported fiscal Q4 2026 revenue of $63.7 billion, up 6%, with GAAP diluted EPS up 70% to $1.70 and non-GAAP diluted EPS up 40% to $2.91. Fiscal year 2026 revenue rose 14% to $254.2 billion and non-GAAP EPS grew 37% to $11.26, with segment profit up double digits across all five operating segments and $5.2 billion of operating cash flow. The company guided fiscal 2027 non-GAAP EPS to $12.40-$12.60, representing 13% to 15% growth and landing above its long-term EPS guidance, with adjusted free cash flow of $3.5-$4.0 billion and ~$1 billion of planned buybacks.

Key figures

Eps: Q4 GAAP $1.70 (+70%); Q4 non-GAAP $2.91 (+40%, $2.60/+25% ex-IEEPA refund); FY26 GAAP $7.23 (+12%); FY26 non-GAAP $11.26 (+37%)
Revenue: $254.2 billion FY2026 ($63.7 billion Q4)
Guidance: FY2027 non-GAAP diluted EPS $12.40-$12.60, +13% to +15% growth, above the company's long-term EPS guidance
Net Income: Q4 $398 million GAAP attributable to Cardinal Health (+67%); FY26 $1.714 billion (+10%)
Revenue Yoy: +14% FY2026 (+6% Q4)
Total Assets: 57299000000
Cash Position: 4856000000
Dividend dates: payable October 15, 2026, record October 1, 2026
Gmpd q4 revenue: $3.1 billion (-2%), Q4 segment profit $150 million vs $70 million ($50 million, -29% ex-refund)
Pharma q4 revenue: $58.8 billion (+6%), Q4 segment profit $645 million (+21%)
Fy27 diluted shares: ~233 million
Fy26 share repurchases: $1.4 billion
Fy27 non gaap tax rate: 19.0%-20.0%
Fy26 operating cash flow: $5.174 billion
Fy27 planned repurchases: ~$1 billion
Ieepa tariff refund gmpd: $100 million ($0.31 EPS impact)
Revolving credit facility: $4.0 billion replacing three historic facilities
Fy27 adjusted fcf guidance: $3.5-$4.0 billion
Outcomes equity impairment: $122 million pre-tax (16% stake)
Q4 gaap operating earnings: $729 million (+70%)
Fy26 adjusted free cash flow: $4.971 billion
Quarterly dividend per share: 0.5158
Incremental buyback authorized: $5.0 billion (total authorization $6.4 billion)
Q4 non gaap operating earnings: $935 million (+30%)
Goodwill impairment navista ion: $184 million pre-tax (FY26)

Price after filing

1 day: +0.3%7 days: -0.6%30 days: +1.5%

Close on the filing date to close N calendar days later (from $236.40). Historical, not a forecast.

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.